Key Takeaways
- A Race Against Blindness has committed $1 million to the Foundation Fighting Blindness and the RD Fund to advance gene-agnostic therapies for inherited retinal diseases
- The funding includes $775,000 for the RD Fund, which will be matched dollar-for-dollar, and $225,000 for a Foundation Fighting Blindness research award
- Gene-agnostic therapeutic approaches could potentially benefit patients across multiple IRD genotypes, expanding treatment opportunities beyond single-gene therapies
The Foundation Fighting Blindness and its venture philanthropy arm, the Retinal Degeneration (RD) Fund, have received a $1 million commitment from nonprofit organization "A Race Against Blindness" to support the development of gene-agnostic therapies for inherited retinal diseases (IRDs), according to an announcement from the Foundation.
The funding is intended to accelerate therapeutic approaches that could benefit patients regardless of the specific genetic mutation underlying their retinal disease, addressing one of the major challenges in the treatment of IRDs, which are associated with hundreds of different disease-causing genes.
Under the commitment, $775,000 will be directed to the RD Fund and matched dollar-for-dollar, effectively increasing the available capital for investments in promising retinal disease programs. The remaining $225,000 will support a Foundation Fighting Blindness research award focused on advancing gene-agnostic treatment strategies.
Gene-agnostic approaches have emerged as an area of growing interest in retinal research because they have the potential to treat broader patient populations than traditional gene replacement therapies, which are generally designed to target a single genetic mutation. Such approaches may include neuroprotective therapies, optogenetics, regenerative medicine strategies, and other technologies aimed at preserving or restoring vision independent of genotype.
The RD Fund, launched by the Foundation Fighting Blindness in 2018, operates as a nonprofit venture investment fund focused on advancing therapies for inherited retinal diseases and dry age-related macular degeneration. The organization seeks to bridge the funding gap between early-stage discoveries and clinical development through mission-related investments in emerging biotechnology companies.
A Race Against Blindness, founded by Stephen and Kristina Johnston following their family's experience with inherited retinal disease, has previously supported research programs targeting retinitis pigmentosa and Bardet-Biedl syndrome. The organization has raised and deployed millions of dollars toward retinal disease research and therapeutic development.
